Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|4|603-610

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.4, 2014-02, pp. : 603-610

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 7, 2015-07 ,pp. : 654-663

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

By  

Oncology, Vol. 84, Iss. 1, 2012-10 ,pp. : 43-56

Karger

Access to resources Recommend Favorite

Olive Oil‐derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies

By  

PHYTOTHERAPY RESEARCH, Vol. 29, Iss. 11, 2015-11 ,pp. : 1776-1782

John Wiley & Sons Inc

Access to resources Recommend Favorite

Limited Significance of Activated Akt-Mammalian Target of Rapamycin Signaling Pathway in Prostate Cancer Progression

By  

Urologia Internationalis, Vol. 93, Iss. 2, 2014-02 ,pp. : 146-151

Karger

Access to resources Recommend Favorite

Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy

By  

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1199-1207

John Wiley & Sons Inc

Access to resources Recommend Favorite